ArticleBMC infectious diseases2026
The measles vaccine's effectiveness during an epidemic: a test negative case control study (Tunisia, 2019).
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the availability of a safe and effective vaccine globally, measles remains a highly contagious viral disease with considerable mortality rates. Measles outbreaks occurred in many countries in 2019. This study aimed to describe the 2019 measles outbreak in Tunisia and to evaluate the effectiveness of measles immunization within the framework of an outbreak.
methodsWe performed a test negative case control study from January to December 2019. All suspected cases during 2019 epidemic in four governorates in Tunisia (Monastir, Mahdia, Kairouan, and Kasserine) and declared to the regional directorate of primary health care (RDPH) were included. The vaccine effectiveness (VE) was calculated using the standard case-control protocol, with the formula VE = (1- odds vaccinated/odds unvaccinated) × 100. In this context, the odds vaccinated/odds unvaccinated represents the adjusted odds ratio for receiving at least one dose of the measles vaccine in comparison to no doses. Data analysis was performed using SPSS version 21.0 software.
resultsDuring our study period, 2688 suspected cases were reported, of which 396 (14.7%) were laboratory confirmed through serological testing. Infants under one year old comprised 42.2% of confirmed cases. The hospitalization rate for suspected cases was 61.5% and 27 deaths were recorded. Among suspected cases with available vaccination records, the majority (70.1%) were unvaccinated. For confirmed measles cases, IgM + seropositivity rates were 81.8% for unvaccinated cohort and 38% in the vaccinated cohort. In outbreak context, the Vaccine Effectiveness (VE) on measles infection was 86.4% (95% CI: 79.2–91.1). The measles outbreak response immunization (ORI) effectiveness on the risk of infection was 97.8% (95% CI: 90.7–99.5). Global VE on the risk of hospitalization was 81% (95%CI: 64.6–89.8) with an ORI of 91.4% (95%CI: 69.0–98.0).
conclusionThe measles outbreak in Tunisia in 2019 led to significant hospitalizations and fatalities, notably affecting infants under 1 year old. The effectiveness of measles vaccination during this outbreak was influenced by vaccination coverage. Implementation of outbreak response immunization (ORI) effectively curbed disease transmission and bolstered herd immunity in the affected areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.